Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glecaprevir - AbbVie/Enanta Pharmaceuticals

Drug Profile

Glecaprevir - AbbVie/Enanta Pharmaceuticals

Alternative Names: ABT-493; Next-generation HCV protease inhibitor - AbbVie/Enanta

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Antivirals; Aza compounds; Cyclic ethers; Cyclopentanes; Cyclopropanes; Quinoxalines; Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 15 Oct 2019 AbbVie completes a phase II non-treatment follow-up trial for Hepatitis C in Canada, Australia, United Kingdom, Puerto Rico, New Zealand, USA, Belgium and Germany (NCT02441283) (EudraCT2015-000452-24)
  • 25 Jun 2019 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in USA (PO)
  • 25 Jun 2019 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive, Treatment-experienced) in USA, Puerto Rico, New Zealand, Australia, Australia, Canada, France, Germany, Italy, Spain, United Kingdom, South Korea, Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top